Contribute Try STAT+ Today

In a closely watched case, a federal appeals court must decide whether a biosimilar company should temporarily pull its product off the market because manufacturing plants may be changed, a move that could cause Americans to pay more for a brand-name biologic medicine — at least for a few months.

At issue is an interpretation of federal law known as the Biologics Price Competition and Innovation Act, which is supposed to determine when biosimilar drugs can be launched. A biosimilar is a nearly identical variant of a biologic and is expected to provide the same result in patients, while costing less money. So the timing of any biosimilar product launch has implications for the U.S. health care system.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.